[
    [
        {
            "time": "",
            "original_text": "【浙商医药|外包】节后普涨，一体化整合是外包发展的重要选择",
            "features": {
                "keywords": [
                    "外包",
                    "节后普涨",
                    "一体化整合"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【浙商医药|外包】节后普涨，一体化整合是外包发展的重要选择",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "凯莱英：拟投资3亿元设立子公司",
            "features": {
                "keywords": [
                    "凯莱英",
                    "投资",
                    "子公司"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英：拟投资3亿元设立子公司",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)：与镇江经开区管委会签署小分子药物综合性研发生产基地项目投资协议 预计投资总额40-50亿元",
            "features": {
                "keywords": [
                    "凯莱英",
                    "镇江",
                    "小分子药物",
                    "研发生产",
                    "投资协议"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：与镇江经开区管委会签署小分子药物综合性研发生产基地项目投资协议 预计投资总额40-50亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "凯莱英：拟以40-50亿元在镇江市投资小分子药物综合性研发生产基地",
            "features": {
                "keywords": [
                    "凯莱英",
                    "镇江",
                    "小分子药物",
                    "研发生产",
                    "投资"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英：拟以40-50亿元在镇江市投资小分子药物综合性研发生产基地",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "凯莱英：拟40亿-50亿元投建小分子药物综合性研发生产基地项目",
            "features": {
                "keywords": [
                    "凯莱英",
                    "小分子药物",
                    "研发生产",
                    "投资"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英：拟40亿-50亿元投建小分子药物综合性研发生产基地项目",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)：拟出资3亿元在镇江设立全资子公司主营小分子CDMO化学原料及原料药研发生产",
            "features": {
                "keywords": [
                    "凯莱英",
                    "镇江",
                    "全资子公司",
                    "小分子CDMO",
                    "研发生产"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：拟出资3亿元在镇江设立全资子公司主营小分子CDMO化学原料及原料药研发生产",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：海外疫情反复 关注三季报业绩预期突出板块",
            "features": {
                "keywords": [
                    "医药行业",
                    "海外疫情",
                    "三季报",
                    "业绩预期"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药行业周报：海外疫情反复 关注三季报业绩预期突出板块",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]